ConductScience.org, home

Paper26258317

Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.

Martin RC and 7 others. Ann Surg, 2015. Cited by 328 papers, by iCite.

Cite this record

ConductScience Library. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Papers, record 26258317. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26258317

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
PubMed
Journal
Ann Surg
PubMed
Year
2015
PubMed
Publication types
Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
328
iCite
Relative citation ratio, by iCite
11.6
iCite
Revised in PubMed
2022-04-08
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martin RC 2ndRobert C G
2Kwon DDavid
3Chalikonda SSricharan
4Sellers MMarty
5Kotz EEric
6Scoggins CCharles
7McMasters KMKelly M
8Watkins KKevin

Source PubMed

Download CSV of authors

Topics26

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
ElectroporationMajor topic
Pancreatic NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Case-Control Studies
Catheter Ablation
Chemoradiotherapy
Combined Modality Therapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
Male
Middle Aged
Minimally Invasive Surgical Procedures
Neoplasm Invasiveness
Neoplasm Staging
Patient Safety
Registries
Retrospective Studies
Risk Assessment
Survival Analysis
Time Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04276857Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic CancerBackgroundClinicalTrials.gov
NCT06231160Clinical Comparative Study of Systematic Therapy Combined With MWA and Systematic Therapy for Pancreatic CancerBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in27257026Shock Therapy for Late-Stage Pancreatic Cancer Gets Closer Look.https://conductscience.org/library/papers/27257026

Source PubMed

Download CSV of comments and corrections

Cited by203

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 328 citations.

PMIDTitleJournalYearIn PapersSource
42928513NCLX Inhibition plus Ca2+ Delivery Potentiates Electroporation and Antitumor Immunity in Pancreatic Ductal Adenocarcinoma.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42928513PubMed
42872478Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results.Oncologist2026https://conductscience.org/library/papers/42872478PubMed
42779964Case Report: Late repeat pancreatic irreversible electroporation in the long-term multidisciplinary management of unresectable pancreatic ductal adenocarcinoma.Front Oncol2026https://conductscience.org/library/papers/42779964PubMed
42688057Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study.Front Oncol2026https://conductscience.org/library/papers/42688057PubMed
42614700Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomater Res2026https://conductscience.org/library/papers/42614700PubMed
42445467Intraoperative irreversible electroporation for margin accentuation in locally advanced intrahepatic cholangiocarcinoma: a case series.Front Surg2026https://conductscience.org/library/papers/42445467PubMed
42397620Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.Curr Oncol Rep2026https://conductscience.org/library/papers/42397620PubMed
42283922Revelations of pancreatic cancer treated by high-intensity focused ultrasound.Discov Oncol2026https://conductscience.org/library/papers/42283922PubMed
42238591Anti-PD-1 blockade reverses low-intensity electric stimulation-driven pancreatic cancer progression.Front Immunol2026https://conductscience.org/library/papers/42238591PubMed
42146443The abscopal effect of IRE combined with anti-PD-1 achieves local ablation and systemic control of PDAC.bioRxiv2026https://conductscience.org/library/papers/42146443PubMed
42107701Production of Large Ellipsoidal Ablations Using Integrated Nanosecond Pulse Irreversible Electroporation Administered via a Single Applicator and Grounding Pad.J Vasc Interv Radiol2026https://conductscience.org/library/papers/42107701PubMed
41920765Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.Clin Cancer Res2026https://conductscience.org/library/papers/41920765PubMed
41917374Interventional management of unresectable pancreatic cancer using transarterial chemoembolization and microwave ablation: a single-center evaluation over 12 years.J Cancer Res Clin Oncol2026https://conductscience.org/library/papers/41917374PubMed
41868439Impact of Voltage on the Production on Spherical Ablations for Integrated Time Nanosecond Pulse Irreversible Electroporation.Bioelectricity2025https://conductscience.org/library/papers/41868439PubMed
41803088Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.Signal Transduct Target Ther2026https://conductscience.org/library/papers/41803088PubMed
41699145Expanded Indications and Role of Pancreatic Cyst/Mass Ablation.Curr Gastroenterol Rep2026https://conductscience.org/library/papers/41699145PubMed
41635510Novel Combination of Irreversible Electroporation and Allogenic Chimeric Antigen Receptor T-Cell Therapy Synergizes Therapeutic Outcomes in a Preclinical Human Pancreatic Cancer Mouse Model.Research (Wash D C)2026https://conductscience.org/library/papers/41635510PubMed
41592550Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer.Korean J Radiol2026https://conductscience.org/library/papers/41592550PubMed
41178530Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41178530PubMed
41149494Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience.Curr Oncol2025https://conductscience.org/library/papers/41149494PubMed

See all 203 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26258317

GET https://conductscience.org/api/papers/v1/26258317/cited_by?page=2